Dr. Galsky on Progression on Immunotherapy in Bladder Cancer

(59)

Dr. Galsky Discusses Neoadjuvant Immunotherapy in Bladder Cancer

(1:36)

Dr. Galsky Discusses Combination Immunotherapy in Bladder Cancer

(1:58)

Dr. Galsky on the Geographic Accessibility of Prostate Cancer Clinical Trials

(2:10)

Dr. Galsky on Targeted Therapies in Bladder Cancer

(2:3)

Matthew Galsky Gives an Overview of Bladder Cancer

(1:35)

Dr. Galsky on the Role of Ipilimumab in Bladder Cancer

(1:9)

Dr. Matthew Galsky - ASCO 2021

(4:22)

Dr. Galsky Discusses the Rationale for the IMvigor130 Study in Bladder Cancer

(2:19)

Dr. Galsky on Neoadjuvant Immune Checkpoint Blockade in Bladder Cancer

(1:35)

Dr. Galsky on Ipilimumab in Bladder Cancer

(1:7)

Matthew Galsky, MD, shares a message for patients regarding clinical progress in bladder cancer

(1:8)

Dr. Matthew Galsky on abiraterone

(3:17)

ASCO GU 2020: Dr. Galsky Provides Insight on Potentially Practice-Changing Studies in Bladder Cancer

(7:40)

Matthew Galsky, MD, discusses how to identify patients that will likely be good responders for I-O

(2:14)

ESMO Dr. Galsky

(2:52)

Dr. Galsky on Resistance to Checkpoint Blockade in Metastatic Bladder Cancer

(59)

Galsky: Adjuvant Chemo vs. Observation in Bladder Cancer

(2:34)

Dr. Galsky on Maintenance Pembrolizumab in Urothelial Cancer

(2:21)

Dr. Galsky on Sequencing Questions in Urothelial Cancer

(1:20)